Imatinib (Glivec®) in chronic myeloid leukemia (CML)

Reading time less than 1 minute Published: May 26, 2003 Publication type:

SBU Assessment

Presents a comprehensive, systematic assessment of available scientific evidence for effects on health, social welfare or disability. Full assessments include economic, social and ethical impact analyses. Experts participate in the work. and the reports are reviewed by independent experts.

Contact SBU

Published: May 26, 2003

Page published May 26, 2003

To top